IRA Maximum Fair Price: What Rounds 2-3 Mean for Hub, Copay, and Specialty Pharmacy Vendors

TL;DR

Thesis

MFP does not reduce the need for pharma services; it changes which services are economically justified. Lower Medicare prices compress specialty-pharmacy spread and selected-drug net revenue, but they add operational work around MTF data exchange, MFP eligibility, refund reconciliation, GTN waterfall rebuilds, foundation routing, and Part B buy-and-bill redesign. The biggest service winners are market access, evidence/HEOR, GTN, and data vendors; the most exposed are spread-dependent specialty pharmacies and labor-heavy hubs that cannot prove conversion or adherence lift (CMS Round 2/3 materials; KFF negotiation overview; CMS dispensing-entity resources).

The buyer thesis is that MFP turns lifecycle management into a vendor-architecture problem. Drugs approaching the 9-year small-molecule or 13-year biologic clock need evidence-package planning, GTN system readiness, hub affordability redesign, and SP cash-flow planning years before selection. For Part B products, the 2028 inclusion of physician-administered drugs means infusion, distributor, and site-of-care partners should be evaluated before MFP mechanics hit the medical benefit.

IRA MFP 101: The Three Rounds of Medicare Price Negotiation

The Inflation Reduction Act of 2022 authorized CMS to negotiate prices directly with manufacturers of selected high-expenditure Medicare drugs. Each round follows a standard cadence: selection, data submission, offer and counter-offer, MFP publication, and a January 1 effectuation date two calendar years after selection. Drugs become eligible 9 years post-approval for small molecules and 13 years for biologics. The selection floor is set at percentages of Non-Federal Average Manufacturer Price: 75% for drugs 9-11 years post-approval, 65% for 12-15 years, and 40% for 16+ years.

Round 1: Effective January 1, 2026

Ten Part D drugs accounted for $56.2 billion in gross Part D spending and 8.8 million beneficiaries. CMS published negotiated prices August 15, 2024. Headline outcomes:

Drug	Manufacturer	Condition	List (2023)	MFP (2026)	Discount
Eliquis	BMS/Pfizer	Anticoagulant	$521/mo	$231	56%
Jardiance	Boehringer	Diabetes	$573/mo	$197	66%
Xarelto	J&J	Anticoagulant	$517/mo	$197	62%
Januvia	Merck	Diabetes	$527/mo	$113	79%
Farxiga	AstraZeneca	Diabetes/HF	$556/mo	$179	68%
Entresto	Novartis	Heart failure	$628/mo	$295	53%
Enbrel	Amgen	Autoimmune	$7,106/mo	$2,355	67%
Imbruvica	AbbVie/J&J	Cancer	$14,934/mo	$9,319	38%
Stelara	J&J	Autoimmune	$13,836/mo	$4,695	66%
NovoLog/Fiasp	Novo Nordisk	Insulin	$495/mo	$119	76%

CMS projects $6 billion in annual Medicare net savings from Round 1. The Round 1 effectuation year (2026) is also the operational proving ground for the Medicare Transaction Facilitator (MTF) and pharmacy refund mechanics that Rounds 2 and 3 will scale into.

Round 2: Selected January 17, 2025; MFPs Published November 25, 2025; Effective January 1, 2027

Fifteen Part D drugs representing approximately $41 billion in gross spending and 5.3 million Medicare beneficiaries. CMS published MFPs on November 25, 2025. Discounts range 38-85% with a projected $12 billion in annual net savings, a 44% reduction versus prior net spending (substantially deeper than Round 1’s 22%).

Drug	Therapeutic Area	List Price	MFP	Discount
Ozempic / Wegovy / Rybelsus (semaglutide)	Diabetes/Obesity	$959/mo	$274/mo	71%
Trelegy Ellipta	COPD/Asthma	$586/mo	$158/mo	73%
Breo Ellipta	Asthma/COPD	$378/mo	$64/mo	83%
Janumet	Diabetes	$604/mo	$91/mo	85%
Tradjenta	Diabetes	$556/mo	$89/mo	84%
Linzess	IBS-C / CIC	$597/mo	$149/mo	75%
Ibrance	Breast oncology	$16,334/mo	$8,167/mo	50%
Pomalyst	Multiple myeloma	$22,075/mo	$8,830/mo	60%
Xtandi	Prostate cancer	$13,292/mo	$6,910/mo	48%
Calquence	CLL	$17,147/mo	$10,288/mo	40%
Ofev	IPF	$13,437/mo	$6,719/mo	50%
Austedo	Neurology (TD/HD)	$8,088/mo	$5,015/mo	38%
Venclexta	CLL / AML	$15,840/mo	$7,920/mo	50%
Dexilant	GERD	$447/mo	$134/mo	70%
Farxiga (add’l)	Diabetes/CKD/HF	$566/mo	$181/mo	68%

Round 3: Selected January 27, 2026; MFPs Due November 30, 2026; Effective January 1, 2028

The first round including physician-administered Part B drugs. 10 Part D plus 5 Part B drugs totaling an estimated $27 billion in Medicare spending. The 15 drugs:

Part D (10): Biktarvy (HIV), Trulicity (GLP-1, following semaglutide into negotiation), Verzenio and Kisqali (breast oncology, compounding the Ibrance margin erosion from Round 2), Erleada (prostate), Lenvima (oncology), Cosentyx (autoimmune), Rexulti (psychiatry), Xeljanz (RA), Anoro Ellipta (COPD).

Part B (5, the first-ever physician-administered negotiation cohort): Entyvio, Orencia, Cimzia, Botox, Xolair. Avalere estimates a minimum 47% average add-on payment reduction when Part B drugs move to MFP from ASP+6%, with medical oncology facing roughly 50% compression and rheumatology 34%.

Cumulatively, Rounds 1-3 cover 40 drugs representing over 36% of total Medicare Part B and D drug spending. The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, expanded the orphan drug exclusion and delayed eligibility for at least 5 products and excluded 3 from future negotiations, modestly slowing the expansion trajectory.

Impact on Hub Services Economics

The prevailing narrative (“lower list price means lower hub fees”) is wrong. Hub fees are structured per-patient-per-month, per-transaction, or FTE-based, not as a percentage of drug list price. A hub program for Pomalyst at $22,075/month WAC and a hub program for Pomalyst at $8,830/month MFP costs the manufacturer roughly the same in hub services. What changes is the mix and the manufacturer’s willingness to pay.

New Scope: MTF Dispense Reporting and MFP Eligibility Attestation

The Medicare Transaction Facilitator (MTF), operational since January 1, 2026, is the single largest new category of manufacturer data work created by the IRA. Key mechanics:

• 14-day refund window. Manufacturers must reimburse dispensing pharmacies the difference between acquisition cost and MFP within 14 days of determining a dispense was MFP-eligible. Pharmacies purchase at WAC on standard 14-day payment terms, so cash flow timing is acute.
• Mandatory MTF enrollment. Both manufacturers and dispensing entities must enroll.
• MFP-eligible patient attestation. Each dispense must be tagged as Medicare-covered for an MFP-eligible indication, then reconciled against manufacturer records.

For hub vendors, this creates a net-new service line: MFP dispense reconciliation and pharmacy refund facilitation. Vendors already operating at the intersection of manufacturer, specialty pharmacy, and patient data are structurally positioned to own this: CareMetx-owned Lash/TheraCom (legacy Lash hub operations now under CareMetx), EVERSANA (ACTICS eBV/ePA plus post-Waltz Health payer connectivity), and ConnectiveRx (Careform noncommercial pharmacy, 2B Rx transactions/year).

CMS-Mandated Access Preservation During Negotiation

CMS requires manufacturers to maintain patient access on all dosage forms and strengths of negotiation-selected drugs. In practice, this means hub programs for Round 2 drugs (announced January 2025) had to remain fully resourced through 2026, even as manufacturers modeled revenue compression. Selected-drug manufacturers cannot use access friction as an economic lever.

Volume Surge at Lower Per-Patient Funding

The $2,000 Part D out-of-pocket cap (effective 2025, indexed to $2,100 in 2026) drove a reported ~50% year-over-year surge in oncology Rx volumes in 2024. Hub vendors must absorb higher case volumes at lower per-patient manufacturer funding, because manufacturer Medicare Manufacturer Discount Program (MDP) liability (10% in initial coverage, 20% in catastrophic) now consumes budget that previously went to patient support services.

This is the core “do more with less” thesis. It rewards AI-augmented hubs. AssistRx cites a reduction in time-to-therapy from 12.2 to 3.7 days via CoAssist digital enrollment. Claritas Rx reports 80% PA denial prediction accuracy. Labor-heavy hubs face margin compression as volumes grow faster than per-patient fees.

For deeper context on hub pricing models and competitive positioning, see the Hub Services Market Analysis.

Impact on Copay and Financial Assistance Vendors

The IRA creates a hard bifurcation between Medicare and commercial copay economics.

Medicare Side: Copay Demand Shrinks, Foundation Routing Grows

Medicare beneficiaries are statutorily ineligible for manufacturer copay cards (federal anti-kickback prohibition). Medicare patient financial assistance runs through: (1) the $2,000 OOP cap, (2) the Medicare Prescription Payment Plan (M3P) introduced 2025 for monthly smoothing, (3) Low-Income Subsidy (LIS, “Extra Help”), and (4) independent charitable foundations (HealthWell Foundation, PAN Foundation, Assistance Fund).

Under the $2,000 cap:

• A patient on Enbrel (Round 1, MFP $2,355/month) previously faced $3,300+ in annual OOP on commercial Medicare Advantage Part D plans. Now the ceiling is $2,000.
• Foundation dollars go 3-5x further per drug. A foundation with a fixed annual budget that previously covered 1,000 patients at $10K per patient can now cover 3,000-5,000 patients at $2,000.
• Hub vendors reorient Medicare patient support toward M3P enrollment, foundation application triage, and LIS qualification rather than manufacturer copay card issuance.

HealthWell Foundation and similar independent foundations become more central to Medicare access strategy, not less, despite lower per-patient payouts.

Commercial Side: Copay Complexity Grows Because MFP Does Not Apply

Commercial copay dynamics are unchanged by MFP. Copay accumulators and maximizers remain operative across an estimated 50-60% of commercially insured lives in 2025-2026, redirecting roughly $4.8 billion in manufacturer copay assistance to plans in 2023 per Drug Channels.

Critically, the “benefit stacking” effect on MFP-selected drugs is asymmetric. When Ozempic drops from $959 to $274 on Medicare, there is no parallel reduction for commercial patients, who still pay against the $959 WAC. This sharpens the commercial-vs-Medicare channel split:

• Medicare channel: 71% lower gross revenue, MDP liability, near-zero copay card utilization, foundation-routed assistance.
• Commercial channel: Unchanged list price, full manufacturer copay card economics, continued accumulator/maximizer friction.

Copay program administrators and hub financial-assistance operators should plan for Medicare copay card volumes to shrink 40-60% for MFP-selected drugs while commercial volumes hold or grow. For vendor comparison in this category, see Copay Processors Comparison.

Impact on Specialty Pharmacy Contracting

Specialty pharmacy is the most operationally and financially disrupted vendor category.

Dispensing Fee Compression

SP economics on branded specialty drugs combine a small acquisition spread plus dispensing and clinical fees. Acquisition spread is the largest variable. On a $22,075/month Pomalyst script at commercial rates, a 2-3% spread is $440-660 per dispense. On an $8,830 MFP-dispensed Pomalyst script, the same percentage spread is $177-265 per dispense. The dispensing infrastructure cost does not scale down.

Long-term care pharmacy analysis from the Senior Care Pharmacy Coalition and ATI Advisory projects a 57% revenue reduction on 2026-negotiated drugs and margin compression from 5.7% to 3.7% operating margin by 2027, a 35% compression in absolute margin points. Independent specialty pharmacies without diversified book-of-business face the sharpest impact.

Big-3 PBM-Owned Specialty Pharmacies

The three PBM-owned specialty pharmacies (Accredo/Evernorth, CVS Specialty Pharmacy, OptumRx Specialty Pharmacy) dispense roughly 65-67% of branded specialty volume. Their MFP exposure is buffered by vertical integration: the PBM captures formulary placement economics and rebate-adjacent revenue even as SP dispensing margin shrinks. Still, the spread-based rebate dynamics that drove 2018-2024 PBM specialty growth compress materially on MFP drugs where CMS has subsumed the rebating function.

See Big 3 PBM-Owned Specialty Pharmacies for a deeper look at how Accredo, CVS Specialty, and Optum have structured their specialty networks.

Cash Flow Mechanics

The 14-day MFP refund clock is operationally painful. 67% of pharmacies surveyed report manufacturer MFP refunds arriving after 22 days (beyond the 14-day policy target), and 60% of pharmacy owners reported using personal savings to sustain operations during the Round 1 rollout per SCPC/ATI data. Independent SPs dispensing high volumes of Round 1 drugs in Q1 2026 felt this acutely. Platforms that facilitate MTF data exchange and pharmacy refund reconciliation (Beacon MFP is one emerging entrant) fill a concrete gap.

340B Collision

340B covered entities purchase at ceiling prices typically 25-50% below WAC. For most Round 1 drugs, 340B ceiling prices remain lower than MFPs per 340B Report sourcing, so covered entities have no economic incentive to switch to MFP purchasing. But on the same dispense, a covered entity and a manufacturer can both claim the discount unless there is a deduplication mechanism.

HRSA launched a 340B Rebate Model Pilot August 2025 targeting MFP-selected drugs. Under the pilot, covered entities would pay full WAC upfront and claim a rebate equal to the WAC-minus-ceiling-price gap within 45 days of dispense. On December 29, 2025, a federal court granted a nationwide preliminary injunction; on February 10, 2026, the court vacated the pilot entirely and remanded to HRSA. HRSA issued an RFI with comments due March 19, 2026.

For SP networks serving 340B contract pharmacy arrangements, the net effect is regulatory uncertainty through mid-2026 with manufacturer workarounds (contract pharmacy restrictions) continuing in parallel. The 340B program itself grew to $81 billion in 2024 (+23% YoY) per Drug Channels.

Impact on Market Access Consulting

The IRA is a structural demand driver for market access consulting, not a headwind. Several new service lines emerged 2023-2026:

Negotiation Preparation and CMS Evidence Packages

CMS requires manufacturers to submit evidence across six dimensions: therapeutic alternative identification, health outcomes, costs and resource use, population-specific impact, patient-centered outcomes, and unmet medical need. Evidence package submission deadlines for Round 3 drugs are March 1, 2026, with $1M/day late penalties. Firms that built the analytical IP in Rounds 1-2 compound that advantage now.

Active players in this work:

• Trinity Life Sciences: IRA negotiation preparation, commercial spillover modeling.
• Avalere Health: therapeutic alternative calculators. Authored the $25B Part B provider add-on payment loss projection for 2028-2032.
• Precision AQ: market access strategy under IRA pricing constraints.
• Lumanity: HEOR and evidence generation scoped specifically for CMS negotiation input.
• ZS Associates: commercial spillover risk modeling (estimated 25-50% additional manufacturer impact in older-skewing therapy areas).
• IQVIA Consulting: combined with its real-world data footprint, a single-vendor solution for both evidence and submission.

Launch Pricing Transformation

IRA-affected classes that historically launched at $50,000-80,000 annually now launch at $120,000-180,000, as manufacturers price for the entire commercial lifecycle since inflation rebates cap post-launch increases. Indication sequencing has also been overturned: every additional indication accelerates the negotiation clock. Pfizer has publicly disclosed applying higher internal hurdle rates for drugs with greater than 20% Medicare Part D revenue exposure.

GTN Waterfall Rebuild

Gross-to-net waterfalls for MFP-affected drugs require complete rebuilds. MFP subsumes the rebate function on Medicare volume (manufacturers no longer negotiate discretionary rebates with Part D plans on selected drugs), while commercial rebate dynamics continue unchanged. The bifurcation creates a two-channel GTN model that was not previously a standard industry construct.

Platform vendors serving this work:

• IntegriChain: Gross-to-Net suite, MFP-settled pricing reconciliation, Medicaid best price exclusion tracking.
• Model N: revenue management and government pricing compliance, MFP workflow integration.
• Revitas / Flex (part of the Model N ecosystem): legacy government pricing accounts.

See the Market Access Consulting article for a broader competitive map.

Impact on Data, Analytics, and RWE Vendors

CMS’s therapeutic alternative framework elevates real-world evidence from a supplementary input to a direct negotiation determinant. CMS identifies real-world comparators (including out-of-class alternatives and generics), uses their net prices as the starting point for negotiation, and adjusts based on comparative clinical benefit. Evidence generation planning for drugs approaching the 9-year (small molecule) or 13-year (biologic) selection window must now begin at Phase II/III, 5-10 years before potential selection.

Vendor beneficiaries:

• IQVIA: unmatched Medicare claims depth, therapeutic alternative modeling.
• Komodo Health: closed-claims longitudinal data for real-world comparator identification.
• MMIT (Norstella): formulary and payer-level reporting for MFP-affected drugs, Part D plan formulary monitoring.
• IntegriChain: GTN and channel analytics for settled-pricing reconciliation.

Vendor Opportunity Landscape: New Categories Emerging

Five categories are net-new or materially reshaped:

Category	What It Is	Active / Emerging Vendors
MFP Dispense Reporting	MTF data exchange, MFP-eligible patient attestation, dispensing entity enrollment	Hub platforms (EVERSANA, CareMetx-owned Lash/TheraCom, ConnectiveRx, Valeris); emerging point solutions (Beacon MFP)
14-Day Pharmacy Refund Facilitation	Manufacturer-to-pharmacy WAC-to-MFP reconciliation within policy window	Distributor patient-services platforms; GTN platforms (IntegriChain, Model N)
Manufacturer-of-Record MFP Reporting	Quarterly Part B inflation rebate reporting; MFP Part D reporting; Medicaid best price exclusion	Model N, IntegriChain, legacy government pricing systems
Settled Pricing Reconciliation	Post-dispense reconciliation of WAC-to-MFP delta across specialty and retail channels	Model N, IntegriChain, large pharma in-house Revenue Accounting
CMS Evidence Package Analytics	Therapeutic alternative identification, cross-class comparative effectiveness, HEOR-for-negotiation	IQVIA, Komodo, Avalere, Trinity Life Sciences, Lumanity, Precision AQ

Vendor Readiness Checklist

For any selected or likely selected drug, the vendor diligence question is whether the operating partner can survive the MFP effectuation year without manual workarounds. Minimum readiness evidence:

Readiness area	What to request
MTF enrollment and dispense reporting	Named owner, test files, exception queue, pharmacy attestation workflow, and reconciliation cadence
Refund timing controls	Process map showing how WAC-to-MFP refund eligibility is determined and how 14-day clock risk is monitored
Benefit-phase and payer-type logic	Distinct workflows for Medicare Part D MFP, Part D non-MFP, commercial, Medicaid, 340B, and foundation routes
340B / MFP deduplication	Data fields and dispute process for claims where 340B eligibility and MFP eligibility collide
GTN data handoff	Interface from hub / SP / distributor data into IntegriChain, Model N, or internal revenue-management systems
Patient-support redesign	M3P, LIS, foundation, adherence, and PAP routing that does not assume manufacturer copay card use in Medicare

The strongest vendors will be those that can show this workflow in production for Round 1 drugs before Round 2 semaglutide volume arrives. For Round 3 Part B drugs, the analogous evidence will be buy-and-bill, infusion-center, specialty-distributor, and provider-add-on-payment workflow, not pharmacy-only MTF mechanics.

Pre-MFP vs. Post-MFP Vendor Economics: A Comparative View

Vendor Economics Lever	Pre-MFP (through 2025)	Post-MFP (2026+)
Hub fees (per-patient-per-month)	Driven by drug complexity, therapeutic area	Largely unchanged; new MTF reporting scope expands total contract value
Medicare copay card volume (selected drugs)	Ineligible for copay cards; manufacturer PAPs and foundations	Foundation routing dominates; M3P coordination adds new service line
Commercial copay card volume (selected drugs)	Accumulator/maximizer mitigation	Unchanged; commercial list prices hold
SP acquisition spread (selected drugs)	2-4% of WAC	2-4% of MFP; absolute dollars fall 40-85%
SP dispensing fees	Manufacturer-paid, sometimes rebate-offset	Same nominal fees, relatively higher share of total SP economics
PBM formulary preference	Rebate-driven	CMS-mandated universal formulary for MFP drugs; rebate lever disappears
Part B add-on payment (infusion)	ASP + 6%	MFP + 6% (2028); minimum 47% compression per Avalere
340B ceiling price vs. MFP	340B well below WAC	340B still below MFP for most Round 1 drugs; deduplication unresolved
Market access consulting demand	Launch pricing, payer contracting	All of the above plus MFP evidence packages, GTN rebuild, indication sequencing
GTN modeling complexity	Single waterfall	Bifurcated: MFP-driven Medicare path, unchanged commercial path
Launch list prices (IRA-affected classes)	$50K-80K/year	$120K-180K/year

Implications

Manufacturers should build MFP readiness into vendor selection by lifecycle stage. Late-stage eligible drugs need immediate GTN, MTF, market access, and hub-workflow contracting. Earlier drugs need indication sequencing, evidence generation, and launch-pricing assumptions that anticipate negotiation. Part B products need a separate workstream for buy-and-bill economics, provider add-on compression, specialty distributor contracts, and infusion-site strategy.

Vendor scorecards should favor platforms that can connect Medicare channel data to commercial channel decisions without flattening the two economics. Medicare copay support shifts toward M3P, foundations, and adherence; commercial copay remains accumulator/maximizer-exposed; 340B remains unresolved; and MFP-selected products require refund and eligibility reconciliation. A vendor that cannot segment those pathways will create false savings in one channel and leakage in another.

What Buyers Should Do Now

If you are launching a drug in an IRA-affected therapeutic class, the strategic consequences reach vendor selection:

Drugs 6-8 Years Post-Approval (Late-Stage Eligible)

Model MFP scenarios now. If your drug is a high-Medicare-share (>30% Part D) primary care, respiratory, diabetes, or oncology agent, selection is probable. Lock in:

• Hub vendor contract language that anticipates new MTF reporting scope and MFP reconciliation.
• GTN platform with MFP-settled pricing support (IntegriChain, Model N) before selection to avoid hurried mid-cycle migration.
• Market access consulting capacity for CMS evidence package work 18 months ahead of selection.

Drugs 3-5 Years Post-Approval

Your indication sequencing strategy is now a pricing strategy. Adding an indication that grows Medicare share accelerates the negotiation clock. Consider:

• Whether to delay pursuit of Medicare-heavy indications until after primary commercial uptake.
• Whether your launch price needs to reflect an assumed MFP discount 4-6 years out.
• Evidence generation planning: Phase III protocols should include real-world comparator arms where feasible.

Part B / Physician-Administered Products

Round 3’s 5 Part B drugs (Entyvio, Orencia, Cimzia, Botox, Xolair) are the canaries. If you operate in infusion, rheumatology, gastroenterology, immunology, or ophthalmology, your buy-and-bill economics will face a 2028 reset. Avalere projects at least $25B in provider add-on payment losses across 2028-2032 on the first 10 Part B drugs alone, with oncology and hematology carrying $12B of that total.

• Engage hospital outpatient department (HOPD) site-of-care strategy. 340B-enabled HOPDs maintain a structural advantage; community practices without 340B access face existential margin pressure.
• Reassess specialty distributor contracts (AmerisourceBergen, McKesson Specialty, Cardinal Specialty) for buy-and-bill support services.
• Plan for infusion center consolidation: hospital acquisition of community practices could paradoxically raise total Medicare costs, but it is the predictable response to Part B add-on compression.

Rare Disease and Orphan Drug Launches

The One Big Beautiful Bill Act (OBBBA, July 2025) expanded the orphan drug exclusion. If your drug has (or could secure) multiple orphan designations, its negotiation eligibility clock may reset or extend. Revisit commercial projections assuming longer windows of non-negotiated pricing, particularly for small molecules where IQVIA has estimated years 10-13 post-launch represent 40% of gross lifetime sales.

What to Watch in 2026-2027

1. Round 2 implementation Q1 2027. The semaglutide MFP at $274/month against a $959 WAC is the single largest Medicare drug cost event in history. Pharmacy cash flow, 340B deduplication workarounds, and foundation capacity will stress-test MFP operational mechanics.
2. CMS Round 4 selection (February 2027, for 2029 effectuation). Expands to 20 drugs per round from 2029 onward. Likely targets: second-wave GLP-1s, newer PCSK9 inhibitors, additional oncology orals.
3. HRSA 340B rebate model redesign. Post-RFI (closed March 2026), HRSA must decide whether to re-propose a pilot or accept the status quo. Manufacturer contract pharmacy restrictions and state-level 340B laws continue to fragment the landscape.
4. Part B infrastructure. Infusion sites, specialty distributors, and buy-and-bill-heavy practices need to be ready for January 1, 2028 MFP effectuation. The MTF does not currently cover Part B; CMS operational guidance on Part B refunds is still evolving.
5. OBBBA implementation. Delayed negotiation eligibility for the 5 affected products and exclusion of 3 others changes the 2027-2030 selection universe and commercial lifecycle math for at least those 8 drugs.
6. AI hub economics. Manufacturers under margin pressure from MFP will push harder on hub efficiency. AI-native entrants (Neon Health, others) claim 80-98% call automation at a fraction of labor cost. Expect 2-3 more PE consolidations in mid-tier hubs in 2026-2027.

Cross-References

• Hub Services Market Analysis: detailed vendor tiers, M&A, technology differentiation.
• Big 3 PBM-Owned Specialty Pharmacies: Accredo, CVS Specialty, Optum market share and network strategy.
• Market Access Consulting: firm-by-firm capability map for IRA preparation work.
• Pharma Services Market Sizing: category TAMs and growth projections across the commercialization value chain.
• Copay Processors Comparison: commercial copay administration vendor landscape.
• Pharma Services Explained: Hub, Specialty Pharmacy, and Financial Assistance: foundational glossary and vendor ecosystem map.

Analysis compiled April 2026. Round 1 MFPs effective January 1, 2026 and Round 2 MFPs scheduled for January 1, 2027 are CMS-confirmed; Round 3 selection (January 27, 2026) is CMS-announced with MFPs due November 30, 2026. Provider add-on projections (Avalere), net savings projections (CMS/CBO), and specialty pharmacy margin analysis (SCPC/ATI) are sourced from public research through Q1 2026. Vendor links reflect profiles published on Rx Almanac as of April 2026.